All In Biotech

NDA 208325 · Kai Pharms INC

Parsabiv

Etelcalcetide · Intravenous

Novel

Last checked: Nov 20, 2026Latest source record: Feb 11, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Feb 7, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

20

9 Phase 3, 2 recruiting

FAERS reports

2,877

1,403 serious, 335 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 8, 2026.

PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. PARSABIV is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ( 1 ) Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations. Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations .

Mechanism: Etelcalcetide is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 7, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
3 products under this application
  • PARSABIV · ETELCALCETIDE 5MG/ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • PARSABIV · ETELCALCETIDE 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • PARSABIV · ETELCALCETIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Etelcalcetide" as an intervention, any sponsor and status, largest first.

All 20 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • underdose247
  • shunt stenosis204
  • nausea192
  • hypocalcaemia151
  • product storage error149
  • blood parathyroid hormone increased145
  • shunt occlusion128
  • blood calcium decreased124
  • diarrhoea116
  • vomiting107
  • circumstance or information capable of leading to medication error82
  • death82

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
2017212
2018918
2019628
2020378
2021251
2022208
2023128
202481
202556
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Kai Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.